ArticleFrontiers in oncology2025
Gamma knife for the treatment of choroidal breast cancer metastasis causing retinal detachment: A case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Choroidal metastasis generally has poor prognosis and most commonly originates from breast carcinomas. While systemic chemotherapy offers therapeutic benefits, local therapies are often necessary for symptom management and tumor control. Gamma knife radiosurgery (GKR), which was originally developed for intracranial lesions, has emerged as a promising treatment for choroidal metastasis, offering high precision and minimized toxicity with fewer ocular side effects compared with conventional radiotherapy. This case report explores the use of GKR in a patient with choroidal and brain metastases from breast carcinoma. Case presentation: A 44-year-old woman with a history of treated left breast carcinoma presented with 3 months' gradual vision loss in her left eye. Her visual acuity at presentation was counting fingers (CF). Imaging revealed a choroidal metastasis along with multiple brain metastases. The patient underwent GKR for both choroidal and intracranial metastases, receiving doses ranging from 16 to 18 Gy at 50%-90% isodose. Following treatment, significant tumor regression was observed, with a marked reduction in retinal detachment and vision improvement to 6/18. At 6 months post-GKR, both the choroidal mass and the retinal detachment had fully resolved; however, her visual acuity remained limited due to foveal atrophy. Conclusion: This case demonstrates the potential of GKR as a noninvasive and effective modality for the simultaneous treatment of choroidal and intracranial metastases. In palliative settings, especially for patients with limited life expectancy, GKR can provide symptomatic relief and improved quality of life with minimal invasiveness, which is particularly valuable for younger patients facing advanced metastatic cancer. The importance of a multidisciplinary approach in the management of complex metastatic diseases is also highlighted. Future studies are warranted to fully define the role of GKR in choroidal metastasis and its long-term sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.